Teriflunomide (Aubagio)


Indications for Prior Authorization:

Aubagio is a non-preferred disease modifying agent for the treatment of relapsing forms of multiple sclerosis when all the criteria below are met

Patients must meet the following criteria for the indication(s) above:

  • 18 years or older, AND
  • Diagnosis of relapsing multiple sclerosis confirmed by a neurologist, AND
  • the patient has tried and failed preferred generic glatiramer; AND  
  • None of these drugs may be used in combination with each other or any other disease modifying therapy including natalizumab (Tysabri), mitoxantrone (Novantrone), alemtuzumab or fingolimod (Gilenya), AND
  • Patient is not taking in combination with leflunomide, AND
  • Patient does not have severe hepatic impairment, AND
  • For females of child baring age: patient is not pregnant

Preferred oral medications for Multiple Sclerosis (MS) include Tecfidera and Gilenya, both also requiring prior authorization documenting the patient has completed a trial of preferred generic glatiramer.


  • 7 mg or 14 mg orally once daily
  • Rosuvastatin: the dose of rosuvastatin should not exceed 10mg once daily in patients taking Aubagio


  • Initial approval for one year
  • Renewal for one year if patient has clinical response

Last review date: November 7, 2019

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.